Loading…
MaxCyte is projected to rise to $1.58 by 2027, a +19% move from its current price of $1.33. MXCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.29 | $1.33 | $1.37 | +0.06% |
| Jul 14 | $1.28 | $1.33 | $1.39 | +0.12% |
| Jul 15 | $1.27 | $1.33 | $1.40 | +0.18% |
| Jul 16 | $1.26 | $1.33 | $1.41 | +0.25% |
| Jul 17 | $1.25 | $1.33 | $1.42 | +0.31% |
| Jul 18 | $1.25 | $1.33 | $1.43 | +0.37% |
| Jul 19 | $1.24 | $1.34 | $1.44 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.24 | $1.34 | $1.44 | +0.43% |
| Week 2 | $1.21 | $1.34 | $1.49 | +0.86% |
| Week 3 | $1.18 | $1.35 | $1.53 | +1.30% |
| Week 4 | $1.17 | $1.35 | $1.57 | +1.73% |
| Week 5 | $1.15 | $1.36 | $1.60 | +2.17% |
| Week 6 | $1.14 | $1.36 | $1.64 | +2.61% |
| Week 7 | $1.13 | $1.37 | $1.67 | +3.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MaxCyte, Inc. is a life sciences company that discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Its product family includes ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc.
was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT is a healthcare stock trading at $1.27 per share with a market cap of $136.04M and a market rank of 4058.
The current price and forecast imply a mixed to bullish longer-term outlook. For 2026 the avg price is $1.27 with ROI 0 and sentiment NEUTRAL.
Longer-term forecasts show growing upside, with notable milestones in 2030, 2040, and 2050 (for example, 2030 avg $2.06 with ROI 62.5; 2040 avg $6.24 with ROI 391; 2050 avg $10.91 with ROI 758.7).
A major floor 49.2% below — a decisive break under it would weaken the trend.
The nearest floor, 17.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 11.5% above — clearing it would confirm fresh momentum.
Key MXCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MXCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.29 | Buy | $1.29 | Buy |
| MA 10 | $1.26 | Buy | $1.26 | Buy |
| MA 20 | $1.21 | Buy | $1.23 | Buy |
| MA 50 | $1.10 | Buy | $1.13 | Buy |
| MA 100 | $0.9425 | Buy | $1.09 | Buy |
| MA 200 | $1.20 | Buy | $1.30 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.93 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 148.43 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 13.19 | Buy |
| Bollinger %B (20,2) | 0.97 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 0.10 | Buy |
| Ultimate (7,14,28) | 75.48 | Sell |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.31 | Buy |
| ADX (14) | 23.35 | Buy |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 and positive momentum.
MXCT is trading above both the 50-day and 200-day moving averages, with SMA50 at $1.02 and SMA200 at $1.21. The stock has a defined support at $1.00 and a resistance at $1.27. The 30-day price range spans from $1.01 to $1.59, indicating recent upward movement within a relatively tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.676 | $1.33 | $1.77 | 0% | Neutral | |
| $1.25 | $1.58 | $2.11 | +19% | Neutral | |
| $1.29 | $1.67 | $2.32 | +26% | Bullish | |
| $1.44 | $1.91 | $2.72 | +43% | Bullish | |
| $1.63 | $2.22 | $3.24 | +67% | Bullish | |
| $1.85 | $2.56 | $3.82 | +92% | Bullish | |
| $2.29 | $3.22 | $4.91 | +142% | Bullish | |
| $2.45 | $3.51 | $5.44 | +164% | Bullish | |
| $2.36 | $3.42 | $5.40 | +157% | Bullish | |
| $2.59 | $3.82 | $6.11 | +187% | Bullish | |
| $3.97 | $6.29 | $10.72 | +373% | Bullish | |
| $6.42 | $11.46 | $21.41 | +762% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.676 | $1.33 | $1.59 | +0.00% |
| August 2026 | $1.17 | $1.38 | $1.67 | +3.50% |
| September 2026 | $1.18 | $1.41 | $1.73 | +2.17% |
| October 2026 | $1.15 | $1.38 | $1.71 | -2.19% |
| November 2026 | $1.14 | $1.37 | $1.71 | -0.46% |
| December 2026 | $1.16 | $1.40 | $1.77 | +2.48% |
Click any year to see its month-by-month MXCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MXCT is projected to trade between $0.676 and $1.77, averaging $1.33 — a potential gain of 0% from today's $1.33. A consolidation phase looks the most probable path here.
MaxCyte's 2027 outlook centres on $1.58, within a $1.25 to $2.11 range. That is up +19% on the projected 2026 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2028, MXCT could reach as high as $2.32, with a base case around $1.67 and support toward $1.29 — roughly +26% from $1.33. Buyers look set to stay in control over this stretch.
Expect MXCT to range from $1.44 to $2.72 through 2029. The $1.91 average target implies a +43% move from current prices. That is up +14% on the projected 2028 average. Momentum favours further upside here.
The MXCT price prediction for 2030 points to an average of $2.22 (low $1.63, high $3.24) — a potential gain of +67% on today's $1.33. Buyers look set to stay in control over this stretch.
In 2031, MXCT is projected to trade between $1.85 and $3.82, averaging $2.56 — a potential gain of +92% from today's $1.33. That is up +15% on the projected 2030 average. Momentum favours further upside here.
MaxCyte's 2032 outlook centres on $3.22, within a $2.29 to $4.91 range. That is up +26% on the projected 2031 average. That marks a +142% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MXCT could reach as high as $5.44, with a base case around $3.51 and support toward $2.45 — roughly +164% from $1.33. Momentum favours further upside here.
Expect MXCT to range from $2.36 to $5.40 through 2034. The $3.42 average target implies a +157% move from current prices. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The MXCT price prediction for 2035 points to an average of $3.82 (low $2.59, high $6.11) — a potential gain of +187% on today's $1.33. Momentum favours further upside here.
In 2040, MXCT is projected to trade between $3.97 and $10.72, averaging $6.29 — a potential gain of +373% from today's $1.33. That is up +65% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MaxCyte's 2050 outlook centres on $11.46, within a $6.42 to $21.41 range. That is up +82% on the projected 2040 average. That marks a +762% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MXCT today (≈ 751.879699 MXCT) could be worth
$8,618.64
+$7,618.64 (+762%) by 2050 · US Dollar
Based on the average projected MXCT price of $11.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MXCTwould be worth at today's price.
$1,000 invested in MXCT on Jul 10, 2025 (≈ 438.596497 MXCT) would be worth
$583.33
-$416.67 (-41.7%) today · 0.58× · US Dollar
Based on a MXCT entry price of $2.28 vs. today's $1.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.22 | $1,094.65 | +9.5% |
| 1 month ago | $1.15 | $1,156.52 | +15.7% |
| 3 months ago | $0.791 | $1,681.42 | +68.1% |
| 6 months ago | $1.36 | $977.94 | -2.2% |
| 1 year ago | $2.28 | $583.33 | -41.7% |
| All time (4.9y) ago | $17 | $78.24 | -92.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MXCT forecast.
Our base-case forecast reaches $2.70 around 2032.
Implied market cap at $2.70: $289.23M
The multi-year forecast shows an upward trajectory from 2026 onward. The 2026 avg is $1.27 with ROI 0 and sentiment NEUTRAL, followed by 2027 avg $1.47 with ROI 16.1 and 2028 avg $1.61 with ROI 27.0. By 2029 the avg is $1.79 with ROI 40.7, and by 2030 the avg is $2.06 with ROI 62.5 and sentiment BULLISH.
Further years show continued gains: 2031 avg $2.51 (ROI 97.9), 2032 avg $3.17 (ROI 150), 2033 avg $3.38 (ROI 166.2), 2034 avg $3.29 (ROI 159.1), and 2035 avg $3.65 (ROI 187.3) with a bullish outlook.
The forecast extends to 2040 with min $3.62, avg $6.24, max $11.36 and ROI 391, still with a BULLISH sentiment; and to 2050 with min $5.39, avg $10.91, max $22.03 and ROI 758.7, also bullish. These figures are estimates and are not guaranteed.
Tap a question to reveal the answer.
2030 avg is $2.06, with a min of $1.46 and a max of $3.15; ROI is 62.5 and sentiment is BULLISH.
The 2026 forecast shows a neutral average price of $1.27 with ROI 0, but the long-term outlook from 2027 onward is bullish, with rising averages and ROI (e.g., 2030 ROI 62.5, 2040 ROI 391, 2050 ROI 758.7). The technical picture also shows bullish momentum (RSI 70).
Yes. The forecast max by 2032 is $5.09 and by 2033 is $5.53, indicating potential to exceed $5 in the coming years.
RSI14 is 70, indicating bullish momentum. The price is above SMA50 ($1.02) and SMA200 ($1.21). Support is at $1.00 and resistance at $1.27. The 30-day range is $1.01 to $1.59.
2040: min $3.62, avg $6.24, max $11.36, ROI 391, sentiment BULLISH. 2050: min $5.39, avg $10.91, max $22.03, ROI 758.7, sentiment BULLISH.
MaxCyte Community Discussion
0Share your MaxCyte price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.